

EPHMRA
ANATOMICAL CLASSIFICATION
GUIDELINES 2021

Section A

Changed Classes/Guidelines: Changes Highlighted

Final Version

Date of issue: 19th December 2020

A2B	ANTIULCERANTS Combinations of specific antiulcerants with other substances, such as anti-infectives against <i>Helicobacter pylori</i> , antispasmodics, gastroprokinetics, that are for ulcers, gastro-oesophageal reflux disease or similar conditions are classified according to the antiulcerant substance. For example, proton pump inhibitors in combination with these anti-infectives are classified in A2B2. Combinations of antiulcerants with non-steroidal anti-inflammatories where the antiulcerant is present for gastric protection are classified in M1A1.	r2020
A2B1	H2 antagonists Includes, for example, cimetidine, famotidine, nizatidine, ranitidine, roxatidine. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6.	R2002
A2B2	Proton pump inhibitors Includes esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole. Combinations of proton pump inhibitors with gastroprokinetics for ulcers, gastro-oesophageal disease or similar conditions are classified here. <u>Includes potassium-competitive acid blockers (P-CABs) such as revaprazan, tegoprazan, vonoprazan, etc.</u>	r2021 0
A2B3	Prostaglandin antiulcerants Includes misoprostol, enprostil.	
A2B4	Bismuth antiulcerants Includes combinations with antacids.	
A2B9	All other antiulcerants Includes all other products containing substances with antiulcerant action where the type of substance is not specified in classes A2B1 to A2B4. Combinations of antiulcerants with antispasmodics are classified in A2B1 to A2B9 according to the type of antiulcerant. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6. Included are, eg carbenoxolone, gefarnate, pirenzepine, proglumide, sucralfate and sofalcone. Herbal combinations are classified in A2X. In Japan, Korea and Taiwan only, sulpiride and other psycholeptics indicated for ulcer use are also included in this group, whilst in all other countries, these compounds are classified in N5A9. Products containing rebamipide for gastric mucosal protection are classified here. Products containing rebamipide and indicated for dry eye are classified in S1K9.	r2020
A2C	Out of use	D2018

A11B	MULTIVITAMINS WITHOUT MINERALS	R2003
	Includes all multivitamin combinations as defined under A11A but without minerals, except all oral preparations containing procaine (see A13A1). Products for general well-being are classified in A13A.	
A11B1	Prenatal	R1993
	Includes those products specifically indicated for vitamin supplementation during pregnancy or lactation.	
A11B2	Paediatric	
	Analogous to A11A2 but without minerals.	
A11B3	GERIATRIC	
	Analogous to A11A3 but without minerals (see also A14A2).	
A11B4	Other multivitamins without minerals	
A11C	VITAMIN A AND D, INCLUDING COMBINATIONS OF THE TWO	
A11C1	Vitamin A	
	Includes combinations of vitamin A with vitamin E, but excludes combinations of vitamin A with vitamin D (see A11C3).	
A11C2	Vitamin D	r2021+
	Excludes combinations of vitamin D with vitamin A (see A11C3).	4
	Products containing vitamin D or its analogues with multiple indications are classified here. Products only for secondary hyperparathyroidism are classified in H4F. Cinacalcet is classified in H4F.	
	<u>Products containing vitamin D that are mainly for vitamin D deficiency but also contain minerals (for example, magnesium) are classified here. Products containing both vitamin D and calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified in A12A.</u>	
	<u>Products containing vitamin D with vitamin E (with and without minerals) are classified here. Products containing vitamin D with vitamin E and with calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified in A12A.</u>	
A11C3	Combinations of vitamin A with vitamin D	R2003
	Products containing halibut or cod liver oil are included in this group. Combinations of vitamin A and/or vitamin D with other vitamins are classified as	

	multivitamins in A11A or A11B.	
--	--------------------------------	--

A11X9	<p>All other vitamins, plain and in combination</p> <p>Includes all other vitamin products such as pantothenic acid, riboflavine (vitamin B2) and para-aminobenzoic acid (PABA). Vitamin K is classified in B2B, and vitamin P in C5C.</p> <p>Includes all vitamin B combinations without vitamin B1 when they do not contain vitamin A or vitamin D.</p> <p>Vitamin B2 with vitamin B6 is classified here.</p> <p>Vitamin B1 with vitamin B2 is classified in A11D9.</p> <p><u>Products containing vitamin D that are mainly for vitamin D deficiency but also contain minerals (for example, magnesium) are classified in A11C2. Products containing both vitamin D and calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified in A12A.</u></p> <p><u>Products containing vitamin D in combination with vitamin E (with and without minerals) are classified in A11C2. Products containing vitamin D with vitamin E and with calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified in A12A.</u></p>	R2003 r2021
-------	---	----------------

A12	MINERAL SUPPLEMENTS	
A12A	<p>CALCIUM PRODUCTS</p> <p>Includes single and combination products promoted for osteoporosis or calcium deficiency, even when indicated for other diseases as well (see A11G2 and A11A4). See also M5B.</p> <p>Products containing both calcium and magnesium to treat deficiency of these minerals are classified here.</p> <p>Products containing calcium and indicated for both hyperphosphataemia and calcium deficiency are classified in V3G2.</p> <p><u>Products containing both vitamin D and calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified here. Products containing vitamin D with vitamin E and with calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified here.</u></p>	r20 21 ¹⁴ 6
A12B	<p>POTASSIUM PRODUCTS</p> <p>Potassium diuretic combinations are classified in C3 (see note under A12C regarding potassium aspartate).</p>	
A12C	<p>OTHER MINERAL SUPPLEMENTS</p> <p>Includes magnesium and/or fluoride products used as alimentary supplements. Potassium and magnesium aspartate are usually indicated in the treatment of cardiac disease and should be classified in C6X. In certain cases, however, when these compounds are indicated as mineral supplements, they should be classified in A12.</p> <p>Products containing both calcium and magnesium to treat deficiency of these minerals are classified in A12A.</p>	r2017
A12C1	Magnesium supplements	R1993
A12C2	Other mineral supplements	

A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	
A16A	<p data-bbox="316 208 1401 241">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</p> <p data-bbox="316 282 1401 353">Includes all alimentary tract and metabolism products not classified elsewhere. Oral preparations containing procaine are classified in A13A1.</p> <p data-bbox="316 394 1401 499">Products containing one or more oral antidiabetic substances in combination with one or more substances from a cardiovascular class where the aim is to treat both the diabetes and the cardiovascular condition are classified in A10X1.</p> <p data-bbox="316 539 1401 573">Products containing teduglutide for short bowel syndrome are classified here.</p> <p data-bbox="316 613 1401 775"><u>Products containing elapegademase or pegademase for severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase are classified in L3A9. for adenosine deaminase deficiency are classified in L3A9.</u></p>	r202 10

B2D	BLOOD COAGULATION	
B2D1	Factor VIII, including substitutes Includes antihaemophilic globulin A, emcizumab, etc. Products containing von Willebrand factor only are classified in B2D9.	r2019
B2D2	Factors II, VII, IX and X Includes antihaemophilic globulin B and prothrombin complex.	
B2D3	Anti-inhibitor-coagulation complex Includes aPCC (activated prothrombin complex concentrate), activated FVII (FVIIa), and eptacog alfa.	R2003
B2D4	Factor XIII	
B2D5	Fibrinogen	
B2D6	Fresh frozen plasma and antihaemophilic plasma	
B2D7	Cohn-Fraction I	
B2D8	Platelet concentrates	
B2D9	Other blood fractions Includes products containing von Willebrand factor (single ingredient).	R2005
B2E	THROMBOPOIETIN AGONISTS Includes products containing thrombopoietin agonists, such as eltrombopag and romiplostim. <u>Products containing oprelvekin for the prevention of severe thrombocytopenia are classified in B6X.</u>	2012r <u>2021</u>
B2F	TISSUE SEALING PREPARATIONS Includes products imitating the physiological process of fibrin formation which are used for tissue sealing, haemostasis and support of wound healing. Products containing thrombin/collagen for the prevention of bleeding prior to implantation of ICDs/pacemakers are classified here.	r2016
B2G	SYSTEMIC HAEMOSTATICS Tissue extracts with haemostatic activity, and including snake venoms causing blood clotting, and hormone products exclusively promoted as haemostatics. Includes products containing parenteral conjugated oestrogens for control of uterine bleeding.	r2019



B6	ALL OTHER HAEMATOLOGICAL AGENTS	R1996
B6A	Out of use; can be reused from 1999.	D1996
B6B	HYALURONIDASE	
B6C	Out of use	D2020
B6D	HEREDITARY ANGIOEDEMA PRODUCTS	I2015
	Includes products containing eg C1 inhibitor/conestat alfa, ecallantide, icatibant, etc when indicated for hereditary angioedema.	
B6X	OTHER HAEMATOLOGICAL AGENTS	r 2021 θ
	Includes haemins. Excluded are those preparations used in the treatment of veins and haemorrhoids (C5) and preparations for dermatological use (D3A).	
	<u>Products containing oprelvekin for the prevention of severe thrombocytopenia are classified here.</u>	

<p>C1D</p>	<p>CORONARY THERAPY EXCLUDING CALCIUM ANTAGONISTS AND NITRITES</p> <p>This group includes all other products indicated for coronary insufficiency and angina pectoris. It includes benziodarone, capobenic acid, carbocromen, cinepazet, cinepazic acid, cloridarol, dilazep, dipyridamole, efloxate, etafenone, fenalcomine, flosequinan, hexobendine, imolamine, ivabradine, medibazine, molsidomine, oxyfedrin, trimetazidine, visnadine. Combinations with nitrites are included in C1E and with beta-blockers are included in C7B.</p>	<p>R2007</p>
<p>C1E</p>	<p>NITRITES AND NITRATES</p> <p>This group includes all nitrites and analogous products and combinations if they are indicated for angina pectoris. Combinations of nitrites with cardiac glycosides are classified in C1A2 and combinations with beta-blockers in C7B.</p>	
<p>C1F</p>	<p>POSITIVE INOTROPIC AGENTS</p> <p>This group includes substances such as amrinone, milrinone, fenoximone, piroximone, xamoterol.</p>	<p>R1994</p>
<p>C1X</p>	<p>ALL OTHER CARDIAC PREPARATIONS</p> <p>This group includes substances such as alprostadil, crateagus glycosides, creatinolphosphate, phosphocreatinine, levocarnitine and ubidecarenone. Combination products are only classified in this group if they contain a substance which is not in the C group.</p> <p><u>Products containing alprostadil for peripheral arterial occlusive disease only are classified in C4A1. Products containing alprostadil for erectile dysfunction only are classified in G4E9. Products containing alprostadil for patent ductus arteriosus only or for multiple indications are classified here.</u></p> <p>Products containing tafamidis for transthyretin amyloid polyneuropathy (TAP) only are classified in N7X. Products containing tafamidis for transthyretin amyloid cardiomyopathy (TAC) only are classified here. Products containing tafamidis for both TAP and TAC are classified in N7X.</p>	<p>r20210</p>

C3	DIURETICS	
C3A	DIURETICS	
	Combinations with potassium belong to C3A1, C3A2 or C3A3.	
C3A1	Potassium-sparing agents plain	
	This group includes all products containing amiloride, triamterene and spironolactone (canrenoic acid) plain.	
C3A2	Loop diuretics plain	r2008
	This group includes all products containing bumetanide, etacrynic acid, etozolin, furosemide, muzolimine, piretanide plain.	
C3A3	Thiazides and analogues plain	r2008
	This group includes all products containing thiazides, eg altizide, bendroflumethiazide, benzyhydrochlorothiazide, butizide, chlorothiazide, cyclopenthiiazide, flumethiazide, hydrochlorothiazide, mebutizide, paraflutizide, teclothiazide, trichlormethiazide and analogues (which act similar to thiazides) eg chlortalidone, clopamide, indapamide, mefruside, tienilic acid, xipamide, trippamide, metolazone, quinethazone, clorexolone and meticrane.	
C3A4	Potassium-sparing agents with loop diuretic combinations	
C3A5	Potassium-sparing agents with thiazides and/or analogue combinations	
C3A6	Out of use; can be reused from 2014.	D2011
C3A7	Vasopressin receptor antagonist diuretics	I2011
	Includes products containing vasopressin receptor antagonists such as conivaptan, mozavaptan and tolvaptan.	
C3A9	Other diuretics	r2021 ††
	Includes eg carboanhydrase inhibitors such as clofenamide and diclorphenamide <u>diclofenamide</u> (when not used for the treatment of glaucoma <u>or primary periodic paralysis</u>), diuretics of vegetable origin etc, ethoxazolamide, isosorbide, mannitol, chlorazanyl; mercury salts are also included in this group.	
	<u>Products containing diclofenamide for primary periodic paralysis are classified in M5X. Products containing diclofenamide for glaucoma are classified in S1E1.</u>	

C4	CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS	
C4A	CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS	R2005
	This group includes all products (including citicoline) which are mainly recommended for cerebral vascular diseases or peripheral circulatory disorders excluding venous diseases. Combination products are only classified in this group if they do not belong to group C1-C3, C7-C11.	
C4A1	Cerebral and peripheral vasotherapeutics excluding calcium antagonists with cerebral activity	r202 <u>1</u>
	Products containing phenoxybenzamine alone, and indicated either for hypertension or BPH are classified here. Products containing cinepazide alone and for vasodilation are classified here. Products containing beperminogene perplasmid for improvement of limb ischaemia are classified here. <u>Products containing alprostadil for peripheral arterial occlusive disease only are classified here. Products containing alprostadil for erectile dysfunction only are classified in G4E9. Products containing alprostadil for patent ductus arteriosus only or for multiple indications are classified in C1X.</u>	
C4A2	Calcium antagonists with cerebral activity	R1993
	Includes, bencyclane, cinnarizine, cyclandelate, flunarizine and nimodipine.	

C10	LIPID-REGULATING/ANTI-ATHEROMA PREPARATIONS Excludes products intended for weight reduction.	R2005
C10A	CHOLESTEROL AND TRIGLYCERIDE REGULATING PREPARATIONS Includes all products regulating cholesterol and triglycerides only. Combinations with products of group C4 should be classified here. Combinations with oral antidiabetic substances are classified in A10X1.	r2010
C10A1	Statins -(HMG-CoA reductase inhibitors) Includes atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin. Combinations of statins with ezetimibe are classified in C10C.	R2006
C10A2	Fibrates Includes bezafibrate, ciprofibrate, clofibrate, clofibride, etofibrate, fenofibrate, gemfibrozil, simfibrate.	I1997
C10A3	Ion-exchange resins Includes cholestyramine, colestipol, polidexide.	I1997
C10A4	PCSK9 inhibitors Includes proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, eg alirocumab, evolocumab.	I2016
C10A9	All other cholesterol/triglyceride regulators Includes ezetimibe, probucol, tiadenol, pyridinolcarbamate and all other products excluding those in C10B. Combinations of ezetimibe with statins <u>or with bempedoic acid</u> are classified in C10C. Nicotinic acid derivatives if indicated in this area are classified here, eg acipimox. Products containing volanesorsen for familial chylomicronaemia syndrome (FCS) are classified here.	r2021 0
C10B	ANTI-ATHEROMA PREPARATIONS OF NATURAL ORIGIN This class includes products of natural origin used for the prevention and treatment of arteriosclerosis, eg omega- <u>3</u> fatty acids, garlic preparations, lecithin. <u>Products containing omega-3 fatty acids for the reduction of triglycerides and/or for the prevention and treatment of arteriosclerosis are classified here. Products</u>	I1997 <u>2021</u>

containing omega-3 fatty acids for other conditions or for multiple uses are classified in V3X.

C10C	<p>LIPID REGULATORS IN COMBINATION WITH OTHER LIPID REGULATORS</p> <p>Includes products containing two or more substances, all of which are lipid regulators. These are combinations of different types of lipid regulator in C10A. For example, products containing a statin in combination with nicotinic acid, or products containing a statin in combination with ezetimibe, are classified here.</p> <p><u>Products containing ezetimibe with bempedoic acid are classified here.</u></p> <p>Combinations of a statin with another statin are classified in C10A1. Combinations of a fibrate with another fibrate are classified in C10A2.</p> <p>Combinations of lipid regulators of natural origin with other lipid regulators of natural origin are classified in C10B.</p> <p>Combinations of a lipid regulating substance from C10A together with a substance from C10B (anti-atheroma preparations of natural origin) are also classified in C10C.</p> <p>Products containing one or more oral antidiabetic substances in combination with one or more substances from a cardiovascular class (C) are classified in A10X1. For example, a combination product containing pioglitazone with simvastatin is classified in A10X1.</p>	r2021 θ
------	--	------------

G1D	GYNAECOLOGICAL ANTISEPTICS Includes those products indicated for gynaecological conditions. Excluded are antiseptics for dermatological use which are classified in D8A and antiseptics for non-human use, which are classified in V5A. <u>Products containing dapivirine (vaginal ring) for the prevention of HIV transmission are classified here.</u>	r20 21 9
------------	---	------------------------

G2	OTHER GYNAECOLOGICALS	
G2A	UTEROTONIC PRODUCTS	r2019
	Includes products used to induce labour (including delivery of placenta) and/or to reduce postpartum haemorrhage. Includes oxytocics and prostaglandins E1 and E2, and products used for cervical dilatation.	
G2B	TOPICAL CONTRACEPTIVES	
G2C	Out of use; can be reused from 2000.	D1997
G2D	PROLACTIN INHIBITORS	R1999
	This group includes products used as prolactin inhibitors and containing bromocriptine, cabergoline, pergolide, quinagolide, terguride etc. Bromocriptine in lower doses (1 mg, 2.5 mg) for sexual disorders is classified here; higher doses for parkinsonism are in N4A. In Japan, bromocriptine is classified in N4A.	
G2E	LABOUR INHIBITORS	I1997
	This group includes products acting as labour inhibitors eg ritodrine.	
G2F	TOPICAL SEX HORMONES	r2021 ⁺ ₉
	This group includes all topical hormones and/or steroids indicated for gynaecological conditions. Transdermal patches and vaginal formulations containing oestrogens and intended for a systemic effect are classified in G3C.	
	<u>Products containing progesterone in topical form (such as gel) for relief of breast pain are classified here.</u>	
G2X	OTHER GYNAECOLOGICAL PRODUCTS	I1997
G2X1	Gynaecological antispasmodics	I1997
	This group includes oral analgesics and antispasmodics indicated exclusively for dysmenorrhoea.	
G2X9	Other gynaecologicals	r2021 ₀
	Specific products included in this class are non-hormonal anti-inflammatories (eg benzydamine) which are indicated specifically to treat gynaecological conditions. Includes lubricants for intimate vaginal use only. Includes products (lactogogues) for the promotion of milk production.	
	Products containing paroxetine (7.5mg daily) and indicated for menopausal vasomotor symptoms are classified here.	
	Products containing bremelanotide or flibanserin and indicated for hypoactive sexual desire disorder (HSDD) in women are classified here.	

Products containing omega-3 fatty acids for use as supplements during pregnancy and when breastfeeding are classified in V3X.

G3C	OESTROGENS, EXCLUDING G3A, G3E, G3F	r2019
	<p>Oestrogens in combination with non-hormonal substances are classified here.</p> <p>Products containing a SERM in combination with an oestrogen and indicated for the short-term treatment of menopausal symptoms together with the prevention of osteoporosis are classified here.</p> <p>Includes transdermal patches and vaginal formulations containing oestrogens and intended for a systemic effect.</p> <p>Products containing parenteral conjugated oestrogens for uterine bleeding are classified in B2G.</p>	
G3D	PROGESTOGENS, EXCLUDING G3A, G3F	R1997 r2021
	<u>Products containing progesterone in topical form (such as gel) for the relief of breast pain are classified in G2F.</u>	
G3E	ANDROGEN WITH FEMALE HORMONE COMBINATIONS	
G3F	OESTROGEN WITH PROGESTOGEN COMBINATIONS, EXCLUDING G3A	
G3G	GONADOTROPHINS, INCLUDING OTHER OVULATION STIMULANTS	
G3H	Out of use; can be reused from 2009.	D2006
G3J	SERMS (SELECTIVE OESTROGEN RECEPTOR MODULATORS)	r2015
	<p>Included in this class are products that contain selective oestrogen receptor modulators, eg lasofoxifene, raloxifene. When primarily indicated for cancer, SERMs are classified in L2.</p> <p>Products containing a SERM in combination with an oestrogen and indicated for the short-term treatment of menopausal symptoms together with the prevention of osteoporosis are classified in G3C.</p>	
G3X	OTHER SEX HORMONES AND SIMILAR PRODUCTS	r2015
	<p>Includes mammary extracts and other hormonal preparations for sexual disorders eg placenta extracts. Cyproterone acetate (tab 10mg) is classified here; higher doses (50 mg) and injectable forms are in L2B2 when used as cytostatics. Includes products containing tibolone.</p> <p>Products containing mifepristone are classified here if indicated as abortifacients alone, or with other indications, or in G3A6 if indicated for emergency contraception.</p> <p>Products containing ulipristal are classified here if indicated for uterine fibroids, or in G3A6 if indicated for emergency contraception.</p>	

--	--	--

G4C4	BPH alpha-antagonists and 5-ARIs, combinations Includes products containing an alpha-adrenergic antagonist and a 5-alpha testosterone reductase inhibitor. If one or more additional substances are included, then the product is classified in G4C7.	I2012
G4C7	BPH 5-ARIs and/or alpha-antagonists in combination with other substances Includes products containing eg tamsulosin with tolterodine, tamsulosin with a substance of natural origin, or tamsulosin with corticosteroids.	r2020
G4C8	Out of use	D2012
G4C9	BPH products, other Includes products of herbal or animal origin, as well as homeopathic products, for BPH. Products containing mepartricine, <i>Serenoa repens</i> , or <i>Pygeum africanum</i> are classified in G4C9 if indicated for BPH. This class also includes herbal products for improving prostatic health. <u>Products containing PDE5 inhibitors for BPH only are classified here.</u>	r2021 2012
G4D	URINARY INCONTINENCE PRODUCTS	I2007
G4D4	Urinary incontinence products This group includes preparations for urinary incontinence eg those containing duloxetine, flavoxate, oxybutynin, tolterodine. Products of natural origin and homeopathic products are classified in G4D8.	I2007
G4D8	Urinary incontinence products of natural origin Includes products of herbal or animal origin, as well as homeopathic products, for urinary incontinence. Also includes collagen injections for incontinence.	I2007

G4E	<p>ERECTILE DYSFUNCTION PRODUCTS</p> <p>Includes products for the treatment of male impotence.</p>	r2015
G4E1	<p>Erectile dysfunction products, PDE5 inhibitors</p> <p>Includes products containing PDE5 inhibitors, eg avanafil, mirodenafil, sildenafil, tadalafil, udenafil, vardenafil, etc, when indicated for the treatment of erectile dysfunction.</p> <p>Products containing sildenafil (oral 20mg) or tadalafil and indicated for pulmonary arterial hypertension (PAH) only are classified in C6B2. Products containing tadalafil and indicated for both erectile dysfunction and PAH are classified here.</p> <p>Products indicated for erectile dysfunction that contain a PDE5 inhibitor in combination with other substances are classified here.</p> <p>Products containing a PDE5 inhibitor in combination with other substances, and indicated for erectile dysfunction as well as other conditions, are classified here.</p> <p><u>Products containing PDE5 inhibitors for BPH only are classified in G4C9.</u></p>	r2021+ 7
G4E9	<p>Erectile dysfunction products, others</p> <p>Includes products containing eg alprostadil, apomorphine, etc when indicated for the treatment of erectile dysfunction. <u>Products containing alprostadil for peripheral arterial occlusive disease only are classified in C4A1. Products containing alprostadil for erectile dysfunction only are classified here. Products containing alprostadil for patent ductus arteriosus only or for multiple indications are classified in C1X.</u></p> <p>In addition, includes products that contain substances of natural origin for erectile dysfunction.</p> <p>Products that do not contain a PDE5 inhibitor and are indicated for erectile dysfunction, together with other urological conditions, are classified here.</p>	r2021 15
G4X	<p>ALL OTHER UROLOGICAL PRODUCTS</p> <p>Includes products containing local anaesthetics used specifically for premature ejaculation.</p> <p>Products for erectile dysfunction are classified in G4E. Products for both erectile dysfunction and other urological conditions are also classified in G4E. Products for improving general sexual performance (not specifically erectile dysfunction) are classified here.</p>	r2015

J5	ANTIVIRALS FOR SYSTEMIC USE	R2018
J5A	Out of use; can be reused from 2001.	D1998
J5B	ANTIVIRALS, OTHER	R2018
	Includes systemic antivirals for herpes, influenza, viral respiratory conditions, etc. Excludes topical skin antivirals (D6D), topical ophthalmic antivirals (S1D), HIV antivirals (J5C), and hepatitis antivirals (J5D).	
J5B1	Out of use	D2018
J5B3	Herpes antivirals	I2008
	Products used against herpes virus infections, including specific systemic forms of products for cytomegalovirus infections (including CMV retinitis), are classified here. Products in topical ophthalmic forms for CMV retinitis are classified in S1D.	
J5B4	Influenza antivirals	I2008 <u>2021</u>
	Includes products indicated specifically for influenza. <u>Products containing favipiravir for influenza only are classified here. Products containing favipiravir for COVID-19 only are classified in J5B5. Products containing favipiravir for both influenza and COVID-19 are classified in J5B5.</u>	
J5B5	Respiratory antivirals excluding influenza products	I2008 <u>2021</u>
	Includes products indicated specifically for respiratory syncytial virus (RSV) infections. Also includes inhalation forms of ribavirin where no indication has been specified.	
	<u>Products containing bamlanivimab, favipiravir, remdesivir, etc specifically for COVID-19 are classified here. Products containing favipiravir for influenza only are classified in J5B4. Products containing favipiravir for both influenza and COVID-19 are classified here.</u>	
	<u>Products containing levilimab for use in COVID-19 are classified in L4C.</u>	
J5B9	Antivirals, others	I2008
	Includes products containing lysozyme for viral infections.	

<p>J5C</p>	<p>HIV ANTIVIRALS</p> <p>Includes antiviral products specifically used to treat HIV (human immunodeficiency virus).</p> <p>Combinations of different classes of HIV antivirals are classified in J5C9. Combinations of HIV antivirals from a single class are classified in that relevant specific class, eg a product containing only two nucleoside reverse transcriptase inhibitors is classified in J5C1.</p> <p>Pentamidine isethionate which is used to treat <i>Pneumocystis carinii</i> in AIDS is classified in P1G.</p> <p><u>Products containing dapivirine (vaginal ring) for the prevention of HIV transmission are classified in G1D.</u></p>	<p>r2021+ 8</p>
<p>J5C1</p>	<p>Nucleoside and nucleotide reverse transcriptase inhibitors</p> <p>Includes abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil, zalcitabine, zidovudine. Single-ingredient products containing tenofovir disoproxil and indicated for either HIV and/or hepatitis are classified here.</p> <p>Products containing single-ingredient lamivudine or tenofovir alafenamide and for hepatitis B only are classified in J5D2.</p>	<p>r2018</p>
<p>J5C2</p>	<p>Protease inhibitors</p> <p>Includes amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir.</p>	<p>r2011</p>
<p>J5C3</p>	<p>Non-nucleoside reverse transcriptase inhibitors</p> <p>Includes delavirdine, efavirenz, etravirine, nevirapine.</p>	<p>r2011</p>
<p>J5C4</p>	<p>HIV antivirals, entry inhibitors</p> <p>Includes products containing entry inhibitors such as enfuvirtide, maraviroc.</p>	<p>I2011</p>
<p>J5C5</p>	<p>HIV antivirals, integrase inhibitors</p> <p>Includes products containing integrase inhibitors eg dolutegravir, elvitegravir, raltegravir.</p>	<p>I2015</p>
<p>J5C9</p>	<p>HIV antivirals, other</p> <p>Includes combinations of different classes of HIV antivirals. Combinations of HIV antivirals from a single class are classified in that relevant specific class, eg a product containing only nucleoside reverse transcriptase inhibitors is classified in J5C1.</p>	<p>r2018</p>

Products containing cobicistat as a single ingredient are classified here. Products containing cobicistat in combination with HIV antivirals are classified in the appropriate class for the antivirals.
--

J7E	VIRAL VACCINES	r2018
	Includes separate classes for vaccines against only one viral group. For vaccines against a combination of bacteria or viruses, see J7B.	
J7E1	Influenza vaccines	I2014
J7E2	Varicella vaccines	I2014
J7E3	HPV (human papillomavirus) vaccines	I2014
J7E4	Hepatitis vaccines	I2014
J7E5	Rotavirus vaccines	I2014
<u>J7E6</u>	<u>Coronavirus vaccines</u>	<u>I2021</u>
	<u>Includes vaccines against COVID-19.</u>	
J7E9	All other viral vaccines	I2014
	Includes all other vaccines against one viral group, eg Japanese encephalitis, measles, mumps, polio, rubella, rabies, tick-borne encephalitis, yellow fever.	
J7F	PROTOZOAL VACCINES	I2018
	Includes separate classes for vaccines against only one protozoal group. For vaccines against a combination of a protozoal group and/or other organisms, see J7B.	
J7F1	Malaria vaccines	I2018
J7F9	All other protozoal vaccines	I2018
J7X	ALL OTHER VACCINE-LIKE PRODUCTS	r2018
	Includes products containing infectious agents and/or their derivatives, eg lysates and extracts of bacteria, that are not strictly considered vaccines.	

L1G	MONOCLONAL ANTIBODY ANTINEOPLASTICS Antineoplastic monoclonal antibodies against protein kinases are classified here and not in L1H.	R2019
L1G1	Monoclonal antibody antineoplastics, CD20 Includes products containing obinutuzumab, ofatumumab, rituximab, rituximab with hyaluronidase, etc.	I2019
L1G2	Monoclonal antibody antineoplastics, VEGF/VEGFR Includes products containing bevacizumab, ramucirumab, etc.	I2019
L1G3	Monoclonal antibody antineoplastics, HER-2 Includes products containing margetuximab, pertuzumab, trastuzumab, <u>trastuzumab deruxtecan</u> , trastuzumab emtansine, etc.	I2019 I2021
L1G4	Monoclonal antibody antineoplastics, EGFR Includes products containing cetuximab, necitumumab, nimotuzumab, panitumumab, etc.	I2019
L1G5	Monoclonal antibody antineoplastics, PD-1/PD-L1 Includes products containing atezolizumab, avelumab, cemiplimab, durvalumab, nivolumab, pembrolizumab, tislelizumab, etc.	I2019

L1G9	<p>Monoclonal antibody antineoplastics, other</p> <p>Includes antibodies with other targets including other CD targets, CTLA-4 (ipilimumab), etc.</p> <p>Includes antibody drug conjugates (ADCs) if not classified with the target class (brentuximab vedotin, gemtuzumab ozogamicin, inotuzumab ozogamicin).</p> <p>Includes radio-labelled antibodies (ibritumomab tiuxetan, tositumomab iodine-131).</p> <p>Includes alemtuzumab, blinatumomab, brentuximab vedotin, catumaxomab, daratumumab, dinutuximab, elotuzumab, gemtuzumab ozogamicin, ibritumomab tiuxetan, inotuzumab ozogamicin, ipilimumab, mogamulizumab, olaratumab, racotumomab, rovalpituzumab tesirine, siltuximab, tositumomab, tositumomab iodine-131, etc.</p> <p>Products containing alemtuzumab and indicated for cancer only are classified here. Products containing alemtuzumab and indicated for multiple sclerosis are classified in N7A.</p>	I2019
L1H	<p>PROTEIN KINASE INHIBITOR ANTINEOPLASTICS</p> <p>Antineoplastic monoclonal antibodies against protein kinases are classified in L1G.</p>	R2019
L1H1	<p>Protein kinase inhibitor antineoplastics, BCR-ABL</p> <p>Includes products containing bosutinib, dasatinib, imatinib, nilotinib, ponatinib, radotinib, etc.</p>	I2019
L1H2	<p>Protein kinase inhibitor antineoplastics, EGFR</p> <p>Includes products containing afatinib, dacomitinib, erlotinib, gefitinib, icotinib, olmutinib, osimertinib, varlitinib, etc.</p>	I2019
L1H3	<p>Protein kinase inhibitor antineoplastics, ALK</p> <p>Includes products containing alectinib, brigatinib, ceritinib, crizotinib, lorlatinib, etc.</p>	I2019
L1H4	<p>Protein kinase inhibitor antineoplastics, BRAF/MEK</p> <p>Includes products containing binimetinib, cobimetinib, dabrafenib, encorafenib, selumetinib, trametinib, vemurafenib, etc.</p>	I2019

L1H5	<p>Protein kinase inhibitor antineoplastics, CDK 4/6</p> <p>Includes products containing abemaciclib, palbociclib, ribociclib, etc. Products containing both ribociclib and letrozole are classified here.</p>	I2019
<u>L1H6</u>	<p><u>Protein kinase inhibitor antineoplastics, BTK</u></p> <p><u>Includes products containing acalabrutinib, ibrutinib, tirabrutinib, zanubrutinib, etc.</u></p>	<u>I2021</u>
L1H9	<p>Protein kinase inhibitor antineoplastics, other</p> <p>Includes all other protein kinase inhibitor antineoplastics, for example those inhibiting HER-2, JAK 1-2, BTK, Pi3K, etc.</p> <p>Includes acalabrutinib, apatinib, axitinib, cabozantinib, erdafitinib, everolimus, ibrutinib, idelalisib, lapatinib, lenvatinib, midostaurin, neratinib, nintedanib, pazopanib, regorafenib, ruxolitinib, sorafenib, sunitinib, temsirolimus, tivozanib, vandetanib, etc.</p> <p><u>Products containing nintedanib for idiopathic pulmonary fibrosis only are classified in R7D. Products containing nintedanib for cancer only are classified here. Products containing nintedanib for both cancer and idiopathic pulmonary fibrosis are classified in R7D.</u></p>	r202 <u>10</u>
L1J	<p>PROTEASOME INHIBITOR ANTINEOPLASTICS</p> <p>Includes products containing proteasome inhibitors for neoplasms, eg bortezomib, carfilzomib, ixazomib, etc.</p>	I2018
L1X	<p>ALL OTHER ANTINEOPLASTICS</p>	R2018
L1X1	<p>Alternative preparations for cancer therapy</p> <p>Includes products derived from Viscum (mistletoe).</p>	r2018
L1X2	<p>Lidomide antineoplastics</p> <p>Includes products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers.</p> <p>Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified here. Products containing thalidomide for ENL only are classified in L4X.</p>	I2019
L1X3	<p>HDAC inhibitor antineoplastics</p>	I2018

L1X4	<p>Includes products containing HDAC inhibitors for neoplasms, eg belinostat, entinostat, panobinostat, romidepsin, tucidinostat, vorinostat, etc.</p> <p>PARP inhibitor antineoplastics</p> <p>Includes products containing niraparib, olaparib, rucaparib, talazoparib, veliparib, etc.</p>	I2019
------	--	-------

L1X5	<p>CAR T-cell therapy antineoplastics</p> <p>Includes products containing axicabtagene ciloleucel, tisagenlecleucel, etc.</p>	I2019
L1X8	<p>Photosensitisers for cancer therapy</p> <p>Includes products containing photosensitisers for use in cancer therapy, eg aminolaevulinic acid, methyl aminolaevulinate, methoxsalen, porfimer, talaporfin, temoporfin, etc.</p> <p>Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified here. Products containing aminolaevulinic acid for use in diagnostic procedures are classified in T1X.</p> <p>Products containing methoxsalen for other skin conditions such as psoriasis or vitiligo are classified in the appropriate D classes.</p> <p>Products containing vertoporphin for macular degeneration are classified in S1P.</p>	r2019
L1X9	<p>All other antineoplastics</p> <p>Includes amsacrine, enzymes, estramustine, gallium nitrate, methylhydralazine, mitotane, procarbazine, substituted urea, tasonermin, vosaroxin. Also includes celecoxib for familial adenomatous polyposis (FAP).</p> <p>Products containing aflibercept for cancer are classified here. Products containing aflibercept for macular degeneration are classified in S1P.</p> <p>Includes products containing hedgehog pathway inhibitors, eg glasdegib, sonidegib, vismodegib, etc.</p> <p>Products containing BCG vaccine for cancer are classified here; those for general immunostimulation are classified in L3A9. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6.</p>	r2020

L3	IMMUNOSTIMULATING AGENTS	I1994
L3A	IMMUNOSTIMULATING AGENTS EXCLUDING INTERFERONS	R2004
L3A1	Colony-stimulating factors Includes aneastim, empegfilgrastim, filgrastim, lenograstim, molgramostim, pegfilgrastim, sargramostim.	r2018
L3A9	All other immunostimulating agents excluding interferons Includes cridanimod, glatiramer acetate, interleukin-2, picibanil. <i>Corynebacterium parvum</i> and levamisole are classified here when used as immunostimulants. Products containing BCG vaccine for cancer are classified in L1X9; those for general immunostimulation are classified here. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6. Products containing elapegademase for adenosine deaminase deficiency are classified here. <u>Products containing elapegademase or pegademase for severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase are classified here.</u>	r2021 0
L3B	INTERFERONS Products containing interferons (with or without ribavirin) for multiple indications are classified in L3B. Products containing interferons (with or without ribavirin) for hepatitis only are classified in J5D1.	r2018
L3B1	Interferons, alpha	I1994
L3B2	Interferons, beta Products containing beta interferons and indicated for multiple sclerosis only are classified in N7A. Products containing beta interferons and indicated for both multiple sclerosis and other conditions are classified here.	R2017
L3B3	Interferons, gamma	I1994
L3B9	Interferons, non-specified	I1994

L4	IMMUNOSUPPRESSANTS	R2010
L4A	Out of use; can be reused from 2013.	D2010
L4B	ANTI-TNF PRODUCTS Products containing anti-TNF substances are classified here, eg adalimumab, afelimomab, certolizumab pegol, etanercept, golimumab, infliximab. These products can be indicated for multiple conditions, eg rheumatoid arthritis, Crohn's disease, psoriasis. Products containing apremilast for psoriatic conditions only are classified in D5B. Products containing apremilast for multiple conditions are classified in L4X.	r2020
L4C	INTERLEUKIN INHIBITORS Includes products containing interleukin inhibitors, eg basiliximab, canakinumab, daclizumab, rilonacept. Includes interleukin inhibitors indicated for the treatment of rejection in organ transplants and for auto-inflammatory diseases such as CAPS (cryopyrin-associated periodic syndromes). Products containing tocilizumab or anakinra and indicated for arthritic conditions are classified in M1C. Products containing tocilizumab and indicated for both arthritic conditions and also giant cell arteritis are classified in M1C. Products containing brodalumab , ixekizumab, secukinumab or ustekinumab and indicated for skin conditions such as psoriasis and also other non-skin conditions, eg rheumatoid arthritis, are classified here. Psoriatic arthritis is defined as a skin condition. Products containing daclizumab and indicated for use in kidney transplantation are classified here. Products containing daclizumab and indicated for multiple sclerosis and other conditions are classified in N7A. Products containing mepolizumab for asthma only or for asthma and EGPA (eosinophilic granulomatosis with polyangiitis) are classified in R3M. Products containing dupilumab for atopic dermatitis are classified in D5X. Products containing dupilumab for both atopic dermatitis and asthma are classified here. Products containing levilimab for use in COVID-19 are classified here.	r2021 0

<p>L4X</p>	<p>OTHER IMMUNOSUPPRESSANTS</p> <p>Immunosuppressants used in the treatment of rejection in organ transplants are classified here, or in L4C if they contain interleukin inhibitors.</p> <p>Includes eg antilymphocyte and antithymocyte immunoglobulins, azathioprine, cyclosporin, muromonab-cd3, mycophenolate mofetil, tacrolimus – unless classified elsewhere because of a specific indication or formulation. For example, ophthalmic cyclosporin for dry eye is classified in S1K9 and dermatological tacrolimus is classified in D5X.</p> <p>Products for multiple sclerosis are classified in N7A. Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified in N7A.</p> <p>Products containing apremilast for psoriatic skin conditions only, are classified in D5B. Psoriatic arthritis is defined as a skin condition. Products containing apremilast for multiple conditions are classified here.</p> <p>Products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers are classified in L1X2. Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified in L1X2. Products containing thalidomide for erythema nodosum leprosum only are classified here.</p> <p>Products containing tofacitinib for multiple conditions are classified here. Products containing tofacitinib for rheumatoid arthritis only are classified in M1C.</p> <p>Products containing leflunomide for multiple conditions are classified here. Products containing leflunomide for rheumatoid arthritis only are classified in M1C.</p> <p><u>Products containing baricitinib for multiple conditions are classified here.</u> <u>Products containing baricitinib for rheumatoid arthritis only are classified in M1C.</u></p> <p>Corticosteroids are not classified here.</p>	<p>r20210</p>
-------------------	---	--------------------------

M1C	<p>SPECIFIC ANTI-RHEUMATIC AGENTS</p> <p>This class includes abatacept, anakinra, tocilizumab, gold preparations, bucillamine, penicillamine and quinolines (eg oxycinchophen). Includes products containing mesalazine, olsalazine, and sulphasalazine if specifically indicated for rheumatic conditions. Products containing aminosalicylates and used for intestinal inflammatory conditions, are classified in A7E1.</p> <p>Azathioprine is in L4X. Products containing methotrexate for rheumatic conditions are classified here; otherwise methotrexate is classified in LIB or in D.</p> <p>Products containing anti-TNF substances are classified in L4B.</p> <p>Products containing tofacitinib, and indicated for rheumatoid arthritis only, are classified here. Products containing tofacitinib for multiple conditions are classified in L4X.</p> <p>Products containing leflunomide, and indicated for rheumatoid arthritis only, are classified here. Products containing leflunomide for multiple conditions are classified in L4X.</p> <p>Products containing interleukin inhibitors and only indicated for arthritic conditions are classified here, eg anakinra. Products containing tocilizumab and indicated for both arthritis and giant cell arteritis are classified here. Other interleukin inhibitors indicated for multiple conditions including arthritis are classified in L4C.</p> <p><u>Products containing baricitinib, and indicated for rheumatoid arthritis only, are classified here. Products containing baricitinib for multiple indications are classified in L4X.</u></p> <p>Psoriatic arthritis is defined as a skin condition.</p>	r2021 0
-----	--	--------------------

M5X	<p>ALL OTHER MUSCULOSKELETAL PRODUCTS</p> <p>Includes all other products for disorders of the musculoskeletal system not classified elsewhere. Includes musculoskeletal products containing substances such as cartilage extract, chondroitin, etc. Products containing chondroitin and glucosamine alone or in combination with other substances are classified here. Combinations of glucosamine with nonsteroidal anti-inflammatories are classified in M1A2. Topical glucosamine and chondroitin products are classified in M2A.</p> <p>Includes hydroquinine indicated for restless leg syndrome.</p> <p>Includes herbal products used for musculoskeletal pain.</p> <p>Products containing burosumab for X-linked hypophosphataemia are classified here.</p> <p>Products containing mexiletine for non-dystrophic myotonic disorders are classified here; products containing mexiletine for cardiac arrhythmias are classified in C1B .</p> <p><u>Products containing diclofenamide for primary periodic paralysis are classified here. Products containing diclofenamide for glaucoma are classified in S1E1. Products containing diclofenamide for diuretic use are classified in C3A9.</u></p>	r2021 0
------------	---	--------------------

N7E	DRUGS USED IN ALCOHOL DEPENDENCE Includes acamprosate, calcium carbimide, disulfiram. Naltrexone when used in alcohol dependence is classified here.	R2002
N7F	DRUGS USED IN OPIOID DEPENDENCE Includes naltrexone, except when used in alcohol dependence (use N7E).	R2002
N7X	ALL OTHER CNS DRUGS Includes parasympathetic agents. Benzodiazepine antagonists such as flumazenil are classified here. Atomoxetine is included in the class. Products containing gabapentin or pregabalin are classified in N3A if indicated for both neuropathic pain and epilepsy. Products containing pilocarpine and indicated for both dry mouth and dry eye are classified here. Products indicated for multiple sclerosis are classified in N7A. Products containing fampridine for improvement in walking in multiple sclerosis are classified here. Products indicated for amyotrophic lateral sclerosis (ALS) are classified here. Products containing tafamidis for transthyretin amyloid polyneuropathy (TAP) only are classified here. Products containing tafamidis for transthyretin amyloid cardiomyopathy (TAC) only are classified in C1X. Products containing tafamidis for both TAP and TAC are classified here. <u>Products containing inebilizumab or satralizumab for neuromyelitis optica spectrum disorder (NMOSD) are classified here.</u>	r2021 0

R5	COUGH AND COLD PREPARATIONS	
R5A	COLD PREPARATIONS WITHOUT ANTI-INFECTIVES This group consists of all products indicated for colds, influenza, etc. It therefore includes combination products such as those containing antihistamines with decongestants, analgesics, antipyretics, vitamins, etc and since symptoms of colds and influenza may include a cough, an antitussive, and possibly an expectorant may also be included (see also R5D2 and R5C).	R1994
R5B	COUGH/COLD PREPARATIONS WITH ANTI-INFECTIVES Includes combinations with anti-infectives (including antivirals) indicated specifically for coughs, colds, influenza and other respiratory conditions. Combinations of antiseptics with expectorants are classified in R5C and with antitussives are classified in R5D2.	r2016
R5C	EXPECTORANTS 'Expectorants' mean substances with secretolytic or secretomotoric activity, so that mucolytics are classified in this group. The group includes all cough preparations with an expectorant as the main ingredient (eg guaiacol, saponin, ammonium chloride). These may also include antihistamines and bronchodilators but excluded are combinations of expectorants with antitussives (R5D2), with analgesics and antipyretics (R5A), and with anti-infectives (R5B). Lozenges indicated for cough and containing expectorants are classified here. Products containing dornase alfa for cystic fibrosis are classified here.	r2021 9
R5D	ANTITUSSIVES	
R5D1	Plain antitussives Includes all plain antitussives.	
R5D2	Antitussives in combinations Includes combinations with expectorants, antihistamines, ephedrine, herbal tinctures, etc. Excluded are combinations with analgesics and antipyretics (R5A) and combinations with anti-infectives (R5B).	R1994
R5E	Out of use; can be reused.	

R7	OTHER RESPIRATORY SYSTEM PRODUCTS	
R7A	RESPIRATORY STIMULANTS Includes centrally acting respiratory stimulants such as lobeline, ethamivan, crotetiamide, croptopamide, nikethamide and doxapram (plain only). Also includes products specifically indicated for primary apnoea in premature newborn babies.	R2006
R7B	CYSTIC FIBROSIS PRODUCTS Out of use; can be reused from 1999. Products containing dornase alfa for cystic fibrosis are classified in R5C.	D1996 I2021
R7B1	Cystic fibrosis transmembrane regulator (CFTR) modulators Includes products containing eg elexacaftor, ivacaftor, lumacaftor, tezacaftor, etc for cystic fibrosis.	I2021
R7C	LUNG SURFACTANTS Includes substances such as colfoscaril palmitate used in neonatal respiratory distress syndrome.	I1996
R7D	IDIOPATHIC PULMONARY FIBROSIS PRODUCTS Includes products containing eg pirfenidone, nintedanib, etc for idiopathic pulmonary fibrosis. Products containing nintedanib for idiopathic pulmonary fibrosis only are classified here. Products containing nintedanib for cancer only are classified in L1H9. Products containing nintedanib for both cancer and idiopathic pulmonary fibrosis are classified here.	I2021
R7X	ALL OTHER RESPIRATORY SYSTEM PRODUCTS Products containing pirfenidone and indicated for the treatment of idiopathic pulmonary fibrosis are classified here.	r20 21 4

S	SENSORY ORGANS	
S1	OPHTHALMOLOGICALS	
S1A	OPHTHALMOLOGICAL ANTI-INFECTIVES	r2009
	Includes plain anti-infectives (antibacterials eg sulphonamides, and antifungals) and all anti-infective combinations with the exception of corticosteroid/anti-infective combinations (S1C). Also excluded are antiseptics (S1G6) and antivirals (S1D).	
S1B	OPHTHALMOLOGICAL CORTICOSTEROIDS	
	Includes plain corticosteroids and all corticosteroid combinations, with the exception of corticosteroid/anti-infective combinations (S1C).	
S1C	OPHTHALMOLOGICAL ANTI-INFLAMMATORY/ANTI-INFECTIVE COMBINATIONS	R2001
S1C1	Ophthalmological corticosteroid and anti-infective combinations	I2001
S1C2	Ophthalmological NSAIDS and anti-infective combinations	I2001
S1C9	Other ophthalmological anti-inflammatory and anti-infective combinations	I2001
S1D	OPHTHALMOLOGICAL ANTIVIRAL AGENTS	r2008
	Includes aciclovir, iododesoxycytidine, idoxuridine, 5-ethyl-2' deoxyuridine, trifluridine, tromantadine, vidarabine. Systemic forms of products for cytomegalovirus retinitis are classified in J5B3.	
S1E	MIOTICS AND ANTIGLAUCOMA PREPARATIONS	
S1E1	Miotics and antiglaucoma preparations, systemic	r2021+ +
	Includes carboanhydrase inhibitors (acetazolamide, diclofenamide and methazolamide), only when they are specifically promoted and used for the treatment of glaucoma (see also C3A9). <u>Products containing diclofenamide for primary periodic paralysis are classified in M5X and for diuretic use are classified in C3A9.</u>	
S1E2	Miotics and antiglaucoma preparations, topical	R2007
	Includes parasympathomimetics (acelidine, acetylcholine, clonidine, pilocarpine); anticholinesterases or cholinesterase inhibitors (carbachol, demecarium bromide, distigmine, ecothiopate iodide, isofluorophate (DFP), neostigmine, paraoxon, physostigmine); sympathicolitics (guanethidine); beta-blockers (bupranolol, timolol); sympathomimetics (adrenaline/epinephrine); prostaglandin analogues; carbo-anhydrase inhibitors.	

V3	ALL OTHER THERAPEUTIC PRODUCTS	
V3A	Out of use; can be reused from 2009.	D2006
V3B	KANPO AND CHINESE MEDICINES	
V3B1	Kanpo medicines	R2003
V3B2	Chinese medicines	R2003
V3C	RADIOPHARMACEUTICALS	R2003
	<p>This group includes medical products which are registered on the Japanese pharmacopoeia and radioactive medicament standard and also includes combination products with radioactive nucleus prescribed by standard provisions.</p> <p>This group excludes products used as diagnostics (see T1).</p> <p>Strontium-89 and similar substances used to treat pain of bone metastases are classified here.</p>	
V3D	DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT	R2005
	Includes amifostine, calcium folinate, calcium levofolate, dexrazoxane, and mesna when indicated for adjuvant therapy in antineoplastic treatment. Products containing calcium folinate and which have multiple indications are classified here.	
V3E	ANTIDOTES	R2007
	Includes products containing eg dimercaprol, edetates, methionine, protamine, pralidoxime. Zinc acetate for Wilson's disease is classified here.	
V3F	IRON-CHELATING AGENTS	I2006
	Includes products containing eg deferiprone, deferoxamine.	
V3G	HYPERKALAEMIA/HYPERPHOSPHATAEMIA PRODUCTS	R2016
V3G1	Hyperkalaemia products	I2016
	Includes products used specifically for hyperkalaemia, eg those containing calcium polystyrene sulfonate, sodium polystyrene sulfonate, patiromer calcium etc.	

V3G2	<p>Hyperphosphataemia products</p> <p>Includes products used specifically for hyperphosphataemia, eg those containing bixalomer, calcium acetate, calcium acetate in combination with magnesium carbonate, calcium carbonate, colestilan, ferric citrate, lanthanum carbonate, sevelamer, sucroferric oxyhydroxide, etc.</p> <p>Products containing calcium and indicated in both hyperphosphataemia and calcium deficiency are classified in V3G2.</p>	I2016
V3H	<p>ANTI-INFLAMMATORY ENZYMES</p> <p>This group includes all enzyme preparations which are indicated to treat inflammatory conditions. Includes enzyme preparations for respiratory conditions. Excluded are enzyme preparations used in digestive conditions which are classified in A9A. Also excluded are specific cholagogues - classified in A5A, enzymatic topical wound treatments - classified in D3A, enzymes for ophthalmic use - classified in S1S9.</p>	R2007
V3X	<p>ALL OTHER THERAPEUTIC PRODUCTS</p> <p>Includes products with multiple anatomical effects, not readily classifiable in any single group. Large packs of chemicals (bulk packs) which are intended for preparation of formulations in the pharmacy/laboratory are classified here. Kelp products are classified here. Includes medical oxygen cylinders.</p> <p><u>Products containing omega-3 fatty acids for the reduction of triglycerides and/or the prevention and treatment of arteriosclerosis are classified in C10B. Products containing omega-3 fatty acids for other conditions (including supplementation in pregnancy and breastfeeding) or for multiple uses are classified here.</u></p> <p>4th level used only in Germany and Hungary.</p>	r 2019 19
V3X1	<p>Umstimmungsmittel preparations of herbal origin</p> <p>Products which are said to intensify the body's defence against infection.</p>	I2006
V3X4	<p>Cure-all preparations</p> <p>These products have a broad spectrum of indications for internal and external use. Includes products containing a mixture of homeopathic together with allopathic or herbal ingredients. These products can have several indications.</p>	I2006
V3X5	<p>Homeopathic preparations (1)</p> <p>Includes single homeopathic dilutions named after the homeopathic ingredient (eg belladonna D3) and complex series. These products can have several indications or the indication is not specified.</p>	I2006

V3X6	<p>Homeopathic preparations (2)</p> <p>Includes homeopathic specialities with a brand name and containing only homeopathic ingredients. These products can have several indications or the indication is not specified.</p>	I2006
V3X7	<p>Dried and cut plants for tea preparations</p> <p>These are packed for sale and have more than one indication, or they are standard registrations.</p>	I2006
V3X9	<p>Other therapeutic preparations</p>	I2006